ONLY FOR HEALTHY WORKERS!
Based on the new data from the Cardiovascular Outcome Studies (CVOTs) of the new antidiabetic drugs, a new edition of the National Guide for Good Clinical Practice - Diabetes Guidelines for 2018 has been published (Revision 2020).
The results of these studies indicate a statistically significant reduction in cardiovascular events in people with type 2 diabetes treated with SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) or GLP-1 RA (liraglutide, semaglutide), dula.
Because we believe that it is extremely important to implement the new recommendations as soon as possible in our country, a mobile application of the national guide for good clinical practice - guidelines for diabetes has been developed.
This way you will always have access to the latest recommendations for dealing with cardiovascular risks and diseases in people with diabetes.
Based on the new data from the Cardiovascular Outcome Studies (CVOTs) of the new antidiabetic drugs, a new edition of the National Guide for Good Clinical Practice - Diabetes Guidelines for 2018 has been published (Revision 2020).
The results of these studies indicate a statistically significant reduction in cardiovascular events in people with type 2 diabetes treated with SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) or GLP-1 RA (liraglutide, semaglutide), dula.
Because we believe that it is extremely important to implement the new recommendations as soon as possible in our country, a mobile application of the national guide for good clinical practice - guidelines for diabetes has been developed.
This way you will always have access to the latest recommendations for dealing with cardiovascular risks and diseases in people with diabetes.
Show More
